Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat in transfusion-dependent lower-risk myelodysplastic syndrome after ESA failure
2024-511348-25-00Phase 3Completed
- Sponsor
- Geron Corporation
- Start
- Dec 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Imetelstat with Placebo to imetelstat (2 arms). Primary endpoint: 8-week red blood cell transfusion independence rate. Started Dec 2015; status: completed.
02
Drugs
imetelstat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-511348-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511348-25-00.